Neose Technologies, Inc.

Novo Nordisk A/s

Cytel Corporation

Ratiopharm Gmbh

Biogenerix Ag

Robert J Bayer

Shawn DeFrees

David A Zopf

Caryn Bowe

Xi Chelsea Chen

David James Hakes

James C Paulson

Shawn Defrees

Murray Ratcliffe

Michael Kriegler

Carl F Perez

Mary M Bendig

S Tarran Jones

Eric Richard Sjoberg

Walter Scott Willett

Michael Nunn

Margaret J Polley

David Jennings Hakes

Robert W Chesnut

Jichao Kang

Susann Taudte

Robert W Chestnut

Krishnasamy Panneerselvam

Grace Mendoza

Krishnasamy Panneer-Selvam

Krishnasamy Paneerselvam

Matthew Kalo

Xi Chen

The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

One pot desialylation and glycopegylation of therapeutic peptides

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Glycopegylation methods and proteins/peptides produced by the methods

Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

Glycopegylated factor IX

Erythropoietin: remodeling and glycoconjugation of erythropoietin

Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF

The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

Glycopegylated erythropoietin

The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

Conjugates between Factor IX and PEG moieties are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

Factor VIII: remodeling and glycoconjugation of factor VIII

Factor VII: remodeling and glycoconjugation of Factor VII

Glycopegylated erythropoietin formulations

Protein remodeling methods and proteins/peptides produced by the methods

This invention provides recombinant glycosyltransferase fusion proteins having a desired level of expression and enzymatic activity (for example, acceptor substrate specificity or catalytic activity). The fusion proteins of the invention have a functional domain of a first glycosyltransferase joined, directly or through a peptide linker, to a subsequence of a functional domain of a second glycosyltransferase. Nucleic acids that encode the fusion proteins are also provided, as are host cells for expressing the fusion proteins and methods of making and using the fusion proteins of the invention.

Fucosyltransferase fusion protein

Growing community of inventors

San Diego, CA, United States of America

Robert J Bayer